However, although targeting TGF-β1 signaling is central to anti-fibrotic therapies, its potential to reverse MASLD remains uncertain (Ahmed et al., 2022). The gene discussed is TGFB1; the disease is metabolic dysfunction-associated steatotic liver disease.